Skip to main content
Erschienen in: Advances in Therapy 10/2016

21.07.2016 | Original Research

Pharmacokinetic Properties of Oral Lafutidine Tablets and the Effect of Food on its Pharmacokinetics in Healthy Chinese Subjects

verfasst von: Shihong Li, Mingzhen Xu, Huqun Li, Juan Du, Weiyong Li

Erschienen in: Advances in Therapy | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The aim of this study was to evaluate the pharmacokinetics (PK) of single and multiple doses of oral lafutidine tablets and the effect of food on the PK properties in healthy Chinese subjects. The tolerability and the effect of gender on the PK properties were also evaluated to acquire more PK information.

Methods

Three PK studies were conducted in 12 healthy Chinese subjects (6 male, 6 female). Study 1 was a single-dose, three-period, three-dose level (10, 20, and 40 mg), three-sequence cross-over study under fasting conditions. Study 2 was a repeat-dose study (10 mg twice daily over 6 days; all 12 subjects). Study 3 was a two-period, two-sequence cross-over single-dose (10 mg) food interaction study. All randomizations (study 1, study 3) were done to ascertain 1:1 gender ratio per sequence. A validated liquid chromatography tandem mass spectrometry (LC/MS/MS) method was used to determine plasma lafutidine concentrations. PK parameters were calculated by the non-compartmental method.

Results

The area under the time–concentration curve (AUC) and maximum plasma concentration (C max) of lafutidine tablets were dose-independent in the single-dose study among these healthy volunteers. The PK parameters of the multiple-dose study were inconsistent with the single study. After administration of a single dose of 10 mg under either fed or fasting conditions, we found that food may not affect the degree of absorption of the lafutidine tablets, but it may slow down the absorption rate. This is shown by the fact that the AUC showed no significant difference while the peak time was significantly delayed under fed conditions.

Conclusion

The PK of lafutidine showed dose proportionality. There was no significant accumulation of lafutidine tablets with multiple dosing. Food did not affect the degree of lafutidine absorption, but it did reduce the rate of absorption. Further study is needed regarding the effect of gender on lafutidine. Lafutidine was well tolerated within the dose range 10–40 mg, and no serious adverse events were observed.
Literatur
1.
Zurück zum Zitat Chen Wei-Dong, Liang Yan, et al. Simple, sensitive and rapid LC–ESI–MS method for the quantitation of lafutidine in human plasma—application to pharmacokinetic studies. J Pharm Biomed Anal. 2006;41:256–60.CrossRefPubMed Chen Wei-Dong, Liang Yan, et al. Simple, sensitive and rapid LC–ESI–MS method for the quantitation of lafutidine in human plasma—application to pharmacokinetic studies. J Pharm Biomed Anal. 2006;41:256–60.CrossRefPubMed
2.
Zurück zum Zitat Onodera S, Shibata M, Tanaka M, Inaba N, Yamaura T, Ohnishi H. Gastroprotective activity of FRG-8813, a novel histamine H2-receptor antagonist, in rats. Jpn J Pharmacol. 1995;68:161–73.CrossRefPubMed Onodera S, Shibata M, Tanaka M, Inaba N, Yamaura T, Ohnishi H. Gastroprotective activity of FRG-8813, a novel histamine H2-receptor antagonist, in rats. Jpn J Pharmacol. 1995;68:161–73.CrossRefPubMed
3.
Zurück zum Zitat Ren Q, Ma B, Yang K, Yan X. Lafutidine-based triple therapy for Helicobacter pylori eradication. Hepatogastroenterology. 2010;57:102–3. Ren Q, Ma B, Yang K, Yan X. Lafutidine-based triple therapy for Helicobacter pylori eradication. Hepatogastroenterology. 2010;57:102–3.
4.
Zurück zum Zitat Shibata M, Yamaura T, Inaba N, Onodera S, Chida Y, Ohnishi H. Gastric anti-secretory effect of FRG-8813, a new histamine H2 receptor antagonist, in rats and dogs. Eur J Clin Pharmacol. 1993;235:245.CrossRef Shibata M, Yamaura T, Inaba N, Onodera S, Chida Y, Ohnishi H. Gastric anti-secretory effect of FRG-8813, a new histamine H2 receptor antagonist, in rats and dogs. Eur J Clin Pharmacol. 1993;235:245.CrossRef
5.
Zurück zum Zitat Yamaura T, Shibata M, Inaba N, Onodera S, Chida Y, Ohnishi H. Effects of FRG-8813, a new-type histamine H2 receptor antagonist, on various experimental gastric and duodenal lesions in rats. Nippon Yakurigaku Zasshi. 1992;99:401.CrossRefPubMed Yamaura T, Shibata M, Inaba N, Onodera S, Chida Y, Ohnishi H. Effects of FRG-8813, a new-type histamine H2 receptor antagonist, on various experimental gastric and duodenal lesions in rats. Nippon Yakurigaku Zasshi. 1992;99:401.CrossRefPubMed
6.
Zurück zum Zitat Lili Wu, Zhang Zunjian, et al. Determination of lafutidine in human plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry: application to a bioequivalence study. J Mass Spectrom. 2005;40:1637–43.CrossRef Lili Wu, Zhang Zunjian, et al. Determination of lafutidine in human plasma by high-performance liquid chromatography-electrospray ionization mass spectrometry: application to a bioequivalence study. J Mass Spectrom. 2005;40:1637–43.CrossRef
7.
Zurück zum Zitat Saegusa Y, Ichikawa T, Iwai T, et al. Effects of acid antisecretory drugs on mucus barrier of the rat against 5-fluorouracil-induced gastrointestinal mucositis. Scand J Gastroenterol. 2008;43:531–7.CrossRefPubMedPubMedCentral Saegusa Y, Ichikawa T, Iwai T, et al. Effects of acid antisecretory drugs on mucus barrier of the rat against 5-fluorouracil-induced gastrointestinal mucositis. Scand J Gastroenterol. 2008;43:531–7.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Kim EH, et al. Efficacy of lafutidine versus famotidine in patients with reflux esophagitis: a multi-center, randomized, double-blind, non-inferiority phase III trial. Dig Dis Sci. 2015;60:1724–1732. Kim EH, et al. Efficacy of lafutidine versus famotidine in patients with reflux esophagitis: a multi-center, randomized, double-blind, non-inferiority phase III trial. Dig Dis Sci. 2015;60:1724–1732.
9.
Zurück zum Zitat Namikawa T, et al. Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer. Anticancer Res. 2014;34(12):7297–301.PubMed Namikawa T, et al. Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer. Anticancer Res. 2014;34(12):7297–301.PubMed
10.
Zurück zum Zitat Yamamoto H, et al. Changes in the mucus barrier during cisplatin-induced intestinal mucositis in rats. Biomed Res Int. 2013;2013:276186.PubMedPubMedCentral Yamamoto H, et al. Changes in the mucus barrier during cisplatin-induced intestinal mucositis in rats. Biomed Res Int. 2013;2013:276186.PubMedPubMedCentral
11.
Zurück zum Zitat Nagano H, Sanai H, Muraoka M, Takagi K. Efficacy of lafutidine, a histamine H2-receptor antagonist, for taxane-induced peripheral neuropathy in patients with gynecological malignancies. Gynecol Oncol. 2012;127(1):172–4.CrossRefPubMed Nagano H, Sanai H, Muraoka M, Takagi K. Efficacy of lafutidine, a histamine H2-receptor antagonist, for taxane-induced peripheral neuropathy in patients with gynecological malignancies. Gynecol Oncol. 2012;127(1):172–4.CrossRefPubMed
12.
Zurück zum Zitat Ikawa K, Shimatani T, et al. Pharmacokinetic and pharmacodynamic properties of lafutidine after postprandial oral administration in healthy subjects: comparison with famotidine. Biol Pharm Bull. 2007;30(5):1003–6.CrossRefPubMed Ikawa K, Shimatani T, et al. Pharmacokinetic and pharmacodynamic properties of lafutidine after postprandial oral administration in healthy subjects: comparison with famotidine. Biol Pharm Bull. 2007;30(5):1003–6.CrossRefPubMed
13.
Zurück zum Zitat Dewan B, Chimata R, et al. An open-label, randomized, cross-over bioequivalence study of lafutidine 10 mg under fasting condition. World J Gastrointest Pharmacol Ther. 2010;1(5):112–8.CrossRefPubMedPubMedCentral Dewan B, Chimata R, et al. An open-label, randomized, cross-over bioequivalence study of lafutidine 10 mg under fasting condition. World J Gastrointest Pharmacol Ther. 2010;1(5):112–8.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Haruki S, Matsumoto H, Kodama K, Tanabe M, Takayanagi H, Cyong J, et al. Pharmacokinetic studies of lafutidime (FRG–8813) in man. Jpn Pharmacol Ther. 1995;23:3049–59. Haruki S, Matsumoto H, Kodama K, Tanabe M, Takayanagi H, Cyong J, et al. Pharmacokinetic studies of lafutidime (FRG–8813) in man. Jpn Pharmacol Ther. 1995;23:3049–59.
Metadaten
Titel
Pharmacokinetic Properties of Oral Lafutidine Tablets and the Effect of Food on its Pharmacokinetics in Healthy Chinese Subjects
verfasst von
Shihong Li
Mingzhen Xu
Huqun Li
Juan Du
Weiyong Li
Publikationsdatum
21.07.2016
Verlag
Springer Healthcare
Erschienen in
Advances in Therapy / Ausgabe 10/2016
Print ISSN: 0741-238X
Elektronische ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-016-0383-9

Weitere Artikel der Ausgabe 10/2016

Advances in Therapy 10/2016 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.